Heron Therapeutics, Inc. (NASDAQ: HRTX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Heron Therapeutics, Inc. (NASDAQ: HRTX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Heron Therapeutics, Inc. (NASDAQ: HRTX) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ... [Yahoo! Finance]
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]